JNJ-7777120
JNJ-7777120 is a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H4 receptor. It has anti-inflammatory effects, and has been demonstrated to be superior to traditional antihistamines in the treatment of pruritus (itching).
See also
References
Canagliflozin
Canagliflozin (INN, trade name Invokana or Sulisent) is a drug of the gliflozin class, used for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson.
Medical use
Canagliflozin is an antidiabetic drug used to improve glycemic control in people with type 2 diabetes. In extensive clinical trials, canagliflozin produced a consistent dose-dependent reduction in HbA1c of 0.77% to 1.16% when administered as monotherapy, combination with metformin, combination with metformin and a sulfonylurea, combination with metformin and pioglitazone, and in combination with insulin from a baselines of 7.8% to 8.1%, in combination with metformin, or in combination with metformin and a sulfonylurea. When added to metformin, canagliflozin 100 mg was shown to be non-inferior to both sitagliptin 100 mg and glimepiride in reductions on HbA1c at one year, whilst canagliflozin 300 mg successfully demonstrated statistical superiority over both sitagliptin and glimiperide in HbA1c reductions. Secondary efficacy endpoint of superior body weight reduction and blood pressure reduction (versus sitagliptin and glimiperide)) were observed as well. Canagliflozin produces beneficial effects on HDL cholesterol whilst increasing LDL cholesterol to produce no change in total cholesterol.
JNJ-42165279
JNJ-42165279 is a drug developed by Johnson & Johnson which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 70nM. It is described as a covalently binding but slowly reversible selective inhibitor of FAAH. JNJ-42165279 is being developed for the treatment of anxiety and major depressive disorder. Clinical development has progressed as far as Phase II human trials with two studies in patients with mood disorders registered in ClinicalTrials.gov.
Following a series of severe adverse events, including a death, in a trial with a different FAAH inhibitor BIA 10-2474, Janssen announced that it was temporarily suspending dosing in its two Phase II clinical trials with JNJ-42165279, headlining the decision as "precautionary measure follows safety issue with different drug in class". Janssen was emphatic that no serious adverse events had been reported in any of the clinical trials with JNJ-42165279 to date. The suspension is to remain in effect until more information is available about the BIA 10-2474 study.
Substance
Substance may refer to:
Music
See also
Substance 1987
Substance (also known as Substance 1987) is a compilation album by English alternative dance band New Order, released in August 1987 by Factory Records. It compiles all of the band's singles at that point in their 12-inch versions, along with their respective B-side tracks. The then-newly released non-album single "True Faith" is also featured, along with its B-side "1963".
Substance was released on vinyl, double CD, double cassette and Digital Audio Tape. It sold over one million copies and became New Order's most popular and critically acclaimed album.
Songs
While Substance presents a sizeable collection of singles, there are many omissions and differences to be found from the original single releases:
Substance (Joy Division album)
Substance is a singles compilation album by the post-punk band Joy Division, released on Factory Records in 1988. It is the companion to a similar singles compilation by their subsequent band New Order, also entitled Substance. It peaked at #7 in the UK album chart and #146 on the Billboard 200, the band's only chart appearance in the United States. It also reached #15 in New Zealand and #53 in Australia in August 1988.
Content
Substance compiles the four singles released by the band that did not appear on albums - "Transmission", "Komakino", "Love Will Tear Us Apart", and "Atmosphere" - as well as their B-sides. It also collects tracks released on extended play singles, the band's first release An Ideal for Living, and two samplers issued by Factory Records, A Factory Sample and Earcom 2: Contradiction. The single "Atmosphere" had been originally issued in France as "Licht und Blindheit" with "Dead Souls" on the B-side. Following the death of Ian Curtis, it was reissued as a posthumous B-side of the "She's Lost Control" single in an alternate version from the track that had previously appeared on Unknown Pleasures. The vinyl version omits the single "Komakino" and does not include the complete titles from the extended plays. Later CD pressings issued by London Records contain a previously unreleased mix of "She's Lost Control" that is slightly different from the original single release. More guitar is featured within the song, the synthesizer melody is shortened and starts at a later point, and the ending of the song is extended by 15 seconds and doesn't fade out.
